← brief for 2026-09-05 · Slowing decline

Cirevetmab, a novel canine anti–TGFβ monoclonal antibody, exerts antifibrotic effects on renal cells in vitro

Paper D Peer reviewed Preclinical

Key takeaways

Cirevetmab is a new antibody drug made for dogs that blocks a body signal called TGF-beta, one of the main drivers of kidney scarring. In dishes of kidney cells it reduced the scarring response. This was done in cells in the lab, not in living dogs or in people, so it is early work with no patient results yet.

Who did this work

Dayna L. Kappenman (Zoetis (United States)) · Christopher L. Koehler (Prognosys Biosciences (United States)) · Reese N. Prentice (Prognosys Biosciences (United States)) · Nadia Koziar (Zoetis (United States)) · Andrew Beardow (Zoetis (United States)) · Alexandre Merlo (Zoetis (United States)) · Christopher S. Knauer (Zoetis (United States)) · Duncan Mwangi (Zoetis (United States)) · Catrina Stirling (Zoetis (United States))

Source

Paper · OpenAlex, CKD works · 2026-09-04
https://doi.org/10.3389/fvets.2026.1885917